RIGL

Rigel Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

30.440

+0.63(2.113%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

30.440

Open

29.950

VWAP

29.71

Vol

818.29K

Mkt Cap

546.01M

Low

28.880

Amount

24.31M

EV/EBITDA(TTM)

4.54

Total Shares

175.41M

486.15M

EV/OCF(TTM)

7.39

P/S(TTM)

2.00

Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

56.11M

+5.21%

65.32M

+13.41%

62.31M

+12.66%

Estimates Revision

The market is revising Upward the revenue expectations for Rigel Pharmaceuticals, Inc. (RIGL) for FY2025, with the revenue forecasts being adjusted by 9.36% over the past three months. During the same period, the stock price has changed by 64.81%.

Revenue Estimates for FY2025

Revise Upward

+9.36%

In Past 3 Month

Stock Price

Go Up

+64.81%

In Past 3 Month

2 Analyst Rating

27.23% Upside

Wall Street analysts forecast RIGL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RIGL is 38.73 USD with a low forecast of 20.45 USD and a high forecast of 57.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

1 Hold

0 Sell

Moderate Buy

27.23% Upside

Current: 30.440

Low

20.45

Averages

38.73

High

57.00

27.23% Upside

Current: 30.440

Low

20.45

Averages

38.73

High

57.00

Citigroup

Yigal Nochomovitz

Strong Buy

Maintains

$49 → $55

2025-03-06

Reason

Citigroup

Yigal Nochomovitz

Price Target

$49 → $55

2025-03-06

Maintains

Strong Buy

Reason

Citi analyst Yigal Nochomovitz raised the firm's price target on Rigel Pharmaceuticals to $55 from $49 and keeps a Buy rating on the shares. The firm says the company has "quietly but deliberately built a solid commercial franchise" over the past three years. The triad of Tavalisse, Rezlidhia plus the more recently acquired Gavreto is emerging with a near $200M in collective sales for 2025, the analyst tells investors in a research note. Citi believes that business alone supports a valuation of $45 per share, or 131% upside from current levels. Rigel's pipeline "also has many interesting features," adds the firm.

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$57

2025-03-05

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$57

2025-03-05

Reiterates

Strong Buy

Reason

B. Riley Securities

Kalpit Patel

Hold

Maintains

$20 → $24

2025-03-05

Reason

B. Riley Securities

Kalpit Patel

Price Target

$20 → $24

2025-03-05

Maintains

Hold

Reason

B. Riley raised the firm's price target on Rigel Pharmaceuticals to $24 from $20 and keeps a Neutral rating on the shares following the Q4 report. The upside was driven primarily by stronger than expected net product sales and an uptick in contract revenues from collaborations, the analyst tells investors in a research note. The firm increased estimates following the earnings report.

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$57

2025-01-23

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$57

2025-01-23

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$57

2025-01-22

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$57

2025-01-22

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$57

2025-01-14

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$57

2025-01-14

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Rigel Pharmaceuticals Inc (RIGL.O) is 25.81, compared to its 5-year average forward P/E of -19.69. For a more detailed relative valuation and DCF analysis to assess Rigel Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-19.69

Current PE

25.81

Overvalued PE

40.34

Undervalued PE

-79.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-10.11

Current EV/EBITDA

4.82

Overvalued EV/EBITDA

13.02

Undervalued EV/EBITDA

-33.24

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

2.86

Current PS

1.79

Overvalued PS

4.64

Undervalued PS

1.08